Articles On Compumedics (ASX:CMP)
Title | Source | Codes | Date |
---|---|---|---|
Check Up: Big week in world of biotech after these 2 Nasdaq stocks announce breakthroughs
Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks There were a couple of big news from the world of biotec... |
Stockhead | CMP | 1 month ago |
Hot Money Monday: This is what the Father of Momentum Investing thought about ‘undervalued’ stocks
Momentum investing has been shown to be a successful strategy over the long term. The strategy essentially involves “buying high, but hoping to sell even higher” – which is the counter to the well known strategy of “buy low and sell high”.... |
Stockhead | CMP | 1 month ago |
Hot Money Monday: ASX is best place in the world to profit from momentum strategy, says this fundie
A momentum trader will essentially be “buying high, but hoping to sell even higher” – which is the counter to the well known strategy of “buy low and sell high”. The biggest question for momentum traders is therefore how to find those stock... |
Stockhead | CMP | 1 month ago |
Closing Bell: ASX ends it like Beckham… lower and with a pretty whimper, which could still suggest good things ahead
The ASX benchmark has closed slightly lower on Friday Losses across the Energy Sector weighed Small caps led ID8 The Aussie sharemarket has ended lower on Friday, driven to a small disgrace by the ongoing declines in oil prices – down... |
Stockhead | CMP | 4 months ago |
Check Up: Biden-Xi meeting could finally end opioids crisis in the US; and recent ASX biotech winners
Xi and Biden set to agree on restricting fentanyl Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks China’s President Xi is expected... |
Stockhead | CMP | 4 months ago |
Closing Bell: Australian stocks go higher, for longer on bets The Fed won’t have to
The ASX has ended Wednesday jumping almost 100 points. Huge effort, everyone Energy Sector misses out on all the positive vibes Small caps led by Findi and Firebrick Pharma The Australian sharemarket is in fine fettle on this Wednesday... |
Stockhead | CMP | 4 months ago |
Check Up: Why Goldman Sachs won’t change its ratings on 3 ASX stocks despite Ozempic-driven selloff
News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks Goldman Sachs analysts said they will make no... |
Stockhead | CMP | 5 months ago |
Check Up: How supramolecular technology is used in biotech, and why L’Oréal wants to get its hands on it
L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks Be... |
Stockhead | CMP | 6 months ago |
CLOSING BELL: ASX sinks to -1.4pc, despite a late tech rally and some sunny Small Caps news
Benchmark slides throughout the day after a shocker on Wall Street last night. Utilities did best but still ended up losing, down 0.3% for the day. Paincheck a ray of sunshine this afternoon, up 33% today despite an early speeding ticket.... |
Stockhead | CMP | 6 months ago |
Closing Bell: Local markets shed 0.6pc as we brace for tonight’s US Fed call
The ASX 200 benchmark falls 0.6% as we brace for news from The Fed Sector losses led by Resources, while Consumers make gains Small caps led by Alderan, and BNPL Sezzle returns Local markets made it a hat trick of losses, with the re... |
Stockhead | CMP | 6 months ago |
Check Up: What is the FDA emergency use authorisation, and which ASX stocks were given approval?
The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks On... |
Stockhead | CMP | 6 months ago |
ASX Biotech August Winners: Sector down despite CSL and Cochlear’s strong results, but don’t panic…
Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August August was all about earnings, and des... |
Stockhead | CMP | 6 months ago |
Check Up: Australian biotech sector continues to be a magnet for US investors
Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the best and worst performing ASX biotechs over the past month The Australian biotech sector co... |
Stockhead | CMP | 6 months ago |
Check Up: Biotech is worth ‘US$4 trillion in 10 years’, and here’s where the smart money will go
Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month Steve Jobs used to say that the most... |
Stockhead | CMP | 7 months ago |
ASX Biotech Winners in July: Down but far from out, here’s why biotechs could stage a comeback
The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July The Covid-19 pandemic had produced windfalls for and attracted fa... |
Stockhead | CMP | 7 months ago |
Check Up: Brisbane based Vaxxas set to disrupt market with game-changing, needle-free vaccines
Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month The world is anticipating a “game changer” as Brisba... |
Stockhead | CMP | 9 months ago |
Check Up: Here’s the handful of ASX small cap health stocks that actually pay dividends
Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week When we talk about dividend-paying hea... |
Stockhead | CMP | 9 months ago |
ASX Biotech Winners in May: We’re finally seeing signs of life on the back of another clinical breakthrough
Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May There are clear signs the biotech sector is springing back to life after a disappointing 2... |
Stockhead | CMP | 9 months ago |
Check Up: Here’s how diabetes drugs can help you get off the beers and lose weight
Pfizer said its diabetes drug works as well as Ozempic for weight loss What are the side effects of these weight loss drugs? Best and worst performing ASX biotechs over the past week Earlier this week, Pfizer surprised the market by say... |
Stockhead | CMP | 10 months ago |
Check Up Budget Edition: Which ASX healthcare stocks will reap benefits from the Budget?
The Federal Budget delivers billions of dollars funding into healthcare and aged care Mental health and Telehealth also received significant funding allocations Here are the ASX stocks that could benefit Medicare, telehealth and mental... |
Stockhead | CMP | 10 months ago |
Check Up: Healthcare is ripe for AI disruption, and Telix Pharma’s first $100m quarterly sales
Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s... |
Stockhead | CMP | 10 months ago |
Top 10 at 10: These ASX seafood, copper and rare earths stocks are getting snapped up in early trade
Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers... |
Stockhead | CMP | 1 year ago |
Check Up: The FDA refuses to give CBD a green light, but market doesn’t seem to care
The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry The US FDA announced last week that:... |
Stockhead | CMP | 1 year ago |
Check Up: Japan’s startup OUI wants to halve the world’s blindness with its smartphone device
Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past... |
Stockhead | CMP | 1 year ago |
Closing Bell: ASX drops 0.41%, RBA predicts more interest rate rises next year
ASX 200 down 0.41% on lower than normal volume Small cap index falls 1.17% and 7 out 11 sectors finish lower RBA raises the cash rate by 25 basis points to 3% The ASX200 was down 0.41% today. The ASX Emerging Companies (XEC) index was... |
Stockhead | CMP | 1 year ago |
How out of favour Biotech has a PR problem and could learn from Dr Karl
ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and... |
Stockhead | CMP | 1 year ago |
Check Up: US FDA approves first clinical trial of naturally derived psychedelic drugs
US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F... |
Stockhead | CMP | 1 year ago |
Market Highlights: US inflation and 5 ASX small caps to watch on Thursday
US inflation is at the highest level in 41 years Wall Street was down, but didn’t react strongly to the data The ASX is set to open flattish US CPI delivered another shock as the latest release showed that headline inflation rose by 9.1%... |
Stockhead | CMP | 1 year ago |
Closing Bell: Volatile? The ASX 200 has criss-crossed its opening level for the 17th time today. (So that’s a yes)
The ASX 200 ends ever so slightly up, XEC finds 0.4% Gains in consumer discretionary, tech offset big losses for energy, resources, materials. South Korea, Kiwi’s lift rates ahead of tonight’s US CPI read Investors are facing crunch time... |
Stockhead | CMP | 1 year ago |
Check Up: These biotech themes got billions in VC funding. These ASX stocks could benefit
A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m... |
Stockhead | CMP | 1 year ago |
Closing Bell: Galileo digging all the right holes today; big miners, not so much
Both ASX Small Cap and benchmark index are down about 0.5% A bleak forecast from Covid-stricken China hits resources stocks Appen in trading halt after jumping 30% Local markets took a turn for the worse on Thursday after Chinese Prem... |
Stockhead | CMP | 1 year ago |
Closing Bell: Tech on sale as risk assets start to look a lot like riskier assets
Aussie small cap index falls flat, day two The ASX200 up 0.65% Conico is 50% higher Rising gold prices and teetering tech stocks are playing dice for the soul of the ASX Emerging Companies (XEC) index on Wednesday, as the small cap top... |
Stockhead | CMP | 1 year ago |
Closing Bell: Local markets cope pretty well with Wall Street bleed
Aussie small cap index falls 1.4% The ASX200 down 1.65% Thursday is Arafura Day! Down less than 2% and I think we can call that a win. No one likes the sight of blood and after the major Wall Street indices shed more than 3.5% a piece,... |
Stockhead | CMP | 1 year ago |
Check Up: Money managers are still bullish on Healthcare; here’s what they said
The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week Dr Anthony Faucci, America’s top infectious disea... |
Stockhead | CMP | 1 year ago |
Check Up: Biotechs are going through a rough patch, but recent ASX IPOs haven’t flopped too badly
The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot... |
Stockhead | CMP | 1 year ago |
Check Up: More clinical trials and FDA funding boost. Is this the end of biotech’s woes?
Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve... |
Stockhead | CMP | 1 year ago |
Check Up: The future of telehealth, and the best and worst performing ASX health stocks for the month
Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal... |
Stockhead | CMP | 2 years ago |
Check Up: Johnson & Johnson manoeuvre causes a stir, as CSL pulls Healthcare higher on the ASX
The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby... |
Stockhead | CMP | 2 years ago |
ASX Tech Stocks: Data3 gains on results forecast, while resignations & appointments mark the new year
The share price in software company Data#3 Limited (ASX:DTL) has risen around ~12% in morning trade to $6.50 after it said its FY22 results are expected to be better than forecast. Profit up Net profit before tax (NPBT) for the first half... |
Stockhead | CMP | 2 years ago |
Closing Bell: Gains across the small cap space as the ASX edges higher
The ASX edged higher in a fairly directionless session in Thursday trade, after US markets comfortably digested the latest round of inflation data overnight. The iron ore majors led the way with strong demand across the board, with more mut... |
Stockhead | CMP | 2 years ago |
ASX Health Stocks: Immuron up 29pc on $6.2m travellers’ diarrhoea clinical study for US military
Immuron nabs $6.2m clinical research deal for US Military strength Travelan dose ECS Botanics reports record revenue of $1.5m expected for Q2 FY22 Compumedics secures first major magnetoencephalography (MEG) sale in China Immuron (ASX:IMC... |
Stockhead | CMP | 2 years ago |
Compumedics secures record sale orders for first half of financial year, inks second MEG sale to Tianjin Normal University
Compumedics has begun the new calendar year with strong sales growth up 33% from the same period last year and a second MEG sale to Tianjin Normal University in China to the tune of $4.2 million. |
Proactive Investors | CMP | 2 years ago |
Market Highlights and 5 ASX Small Caps to watch on Wednesday
US markets were more buoyant overnight, after Federal Reserve Chairman Jerome Powell provided some extra context around the bank’s policy tightening plans. In testimony to Congress, Powell reiterated the Fed will end its asset purchase prog... |
Stockhead | CMP | 2 years ago |
Closing Bell: ASX limps into the close while a post-COVID ‘meme stonk’ roars higher
It was a lacklustre session for local stocks in Tuesday trade, as the ASX 200 limped into the close with a fall of 0.77% while the microcap Emerging Companies index traded flat. In an environment of rising bond yields, the broader tone is s... |
Stockhead | CMP | 2 years ago |
Closing Bell: ASX treads water while an IPO dips on debut
Local stocks made a cautious start to the week, following a fairly volatile trading period last week as jitters stemming from rising bond yields dimmed risk sentiment on global markets. The ASX 200 opened in the red before clawing back some... |
Stockhead | CMP | 2 years ago |
Check Up: As Omicron rages, rapid antigen testing specialist Atomo surges nearly 50pc
At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform... |
Stockhead | CMP | 2 years ago |
Check Up: Anteotech riding high with $1.9m refund, and Avecho inks supply agreement for CBD arthritis treatment
It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining. Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %... |
Stockhead | CMP | 2 years ago |
Compumedics creates local jobs with wearable medtech device
|
Proactive Investors | CMP | 2 years ago |
Check Up: Neuren close to FDA drug approval and Compumedics fires up Aussie factory for medical wearables
It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining. Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont... |
Stockhead | CMP | 2 years ago |
Check Up: Sustainable Nutrition riding high and Singular Health branches out from… health
It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining. Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M... |
Stockhead | CMP | 2 years ago |